Protective Effect of EPA on Cardiovascular Events
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study was to test the hypothesis that the long-term use of highly (＞98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.
| Condition | Intervention | Phase |
|---|---|---|
|
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease |
Drug: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) |
- Major coronary events (sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina pectoris including hospitalization for ischemic episodes,events of angioplasty/ stenting or coronary artery bypass grafting)
- All-cause mortality
- Stroke
- Peripheral artery disease; and
- Cancer
| Estimated Enrollment: | 18000 |
| Study Start Date: | November 1996 |
| Estimated Study Completion Date: | November 2004 |
Epidemiological studies from many countries including Finland, Italy, Japan, and The Netherlands have suggested that an increased intake of dietary fish or fish oil rich in the long-chain polyunsaturated n-3 fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is inversely related to the risk of atherothrombotic diseases, in particular coronary artery disease (CAD).
Results of many prospective observational cohort studies have found that diets rich in marine PUFAs may be protective against major cardiovascular events, including mortality from CAD, total cardiovascular death, all-cause mortality, and nonfatal myocardial infarction. To date, only a few studies have examined the effects of purified n-3 PUFA preparations in human subjects for short observation periods. The principle aim of the current study is to test the hypothesis that the long-term use of highly purified EPA(eicosapentaenoic acid: 1800mg/day), in addition to HMG-CoA reductase inhibitor, is effective in preventing cardiovascular events in Japanese patients with hypercholesterolemia.
Eligibility| Ages Eligible for Study: | 40 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible participants had a total cholesterol level of ≧250mg/dL(6.5m mol/L) at baseline.
- Hyperlipidemic patients with serum total cholesterol of 250mg/dL or more. (Measurement of serum total cholesterol)
- Serum total cholesterol should be measured twice at interval of 2-4weeks. A single measurement is acceptable if the cholesterol is measured by blood collection at fasting under strict compliance with dietary advice after withdrawal of the antihyperlipemic drug.
- (Wash Out) The wash out period of 4weeks (8 weeks for probucol) is necessary in patients under treatment with antihyperlipemic drug. However, if treatment with the antihyperlipemic drug was started within 6 months of the initiation of the study, the patient can participate in the study without the washout period.
Exclusion Criteria:
- Acute myocardial infarction occurring within last 6 months
- Unstable angina pectoris
- A history or complication of serious heart disease(severe arrhythmia, heart failure, cardiac myopathy, valvular disease, congenital disease, etc.)
- Receiving cardiovascular reconstruction within last 6 months
- Cerebrovascular disorders occurring within last 6 months
- Complication of serious hepatic disease or renal disease
- Malignant tumor
- Uncontrollable diabetes
- Hyperlipidemia arising from the following disease: Nephrotic syndrome, hypothyroidism, Cushing’s syndrome, secondary hyperlipidemia due to other disease
- Hyperlipidemia due to some drugs such as steroid hormone
- Hemorrhage(hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.)
- Hemorrhagic diathesis
- Hypersensitivity to the study drug formulation
- Patients intending to undergo surgery
- Patients judged to be inappropriate by the physician in charge
Contacts and Locations| Japan | |
| Kobe University Graduate School of Medicine Cardiovascular and Respiratory Medicine Division, Department of Internal Medicine | |
| Kobe, Hyogo-prefecture, Japan, 650-0017 | |
| Principal Investigator: | Mitsuhiro Yokoyama, MD, PhD. |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00231738 History of Changes |
| Other Study ID Numbers: | No |
| Study First Received: | October 3, 2005 |
| Last Updated: | October 3, 2005 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Kobe University:
|
Eicosapentaenoic acid Coronary artery disease |
Additional relevant MeSH terms:
|
Angina Pectoris Angina, Unstable Infarction Myocardial Infarction Death, Sudden, Cardiac Death Peripheral Arterial Disease Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Chest Pain Pain Signs and Symptoms |
Ischemia Pathologic Processes Necrosis Heart Arrest Death, Sudden Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases Peripheral Vascular Diseases Eicosapentaenoic acid ethyl ester Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013